A new paper discussing the results of The Oxford Vaccine Centre’s COVID-19 ‘COV009‘ vaccine study has been published in Elsevier

Participants from the COV001 and COV002, which were first in human trials of the ChAdOx1-nCoV19 vaccine, were invited to enrol in the COV009 study which aims to further characterize the ongoing safety and immunogenicity of ChAdOx1-nCoV19. The COV009 participants were followed up for 12 months and Serious adverse events (SAEs) and adverse events of special interest (AESIs) were captured.

Read about the findings of the study in the paper here:

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses